As vaccine development continues to evolve in complexity and urgency, DelRicht Research stands out as a high-performing site network delivering results across infectious disease studies. With over 16 vaccine trials completed in the past five years and 10,000+ participants enrolled, our physician-led teams bring both depth of experience and operational scale to every study.

As regulatory expectations grow, including newly reinforced FDA guidance calling for placebo-controlled designs in vaccine studies, the need for experienced, scalable site partners has never been greater.

Trusted Experience Across 17+ Vaccine Sites

DelRicht’s dedicated vaccine research infrastructure spans over 17 active sites nationwide. Each location is fully equipped with secure IP storage, access to local laboratories, and onsite specialty care providers, allowing for seamless execution of even the most protocol-intensive trials. Our principal investigators are nationally recognized experts in immunology, infectious disease, and preventive care, bringing more than 300 years of combined experience to the table.

We know that successful vaccine research depends on reliable, high-volume enrollment and patient follow-through. Our integrated support model ensures both. Full-time site staff are trained in vaccine education, provide real-time consent support, and proactively follow up to ensure adherence. This hands-on approach has contributed to a 92% average diary compliance rate across recent vaccine trials.

Embedded Access to High-Priority Populations

What sets DelRicht apart is our embedded site model, placing research operations directly within local, trusted community clinics. This enables not only faster enrollment, but more inclusive participation. On average, our vaccine trials achieve over 45% diversity in enrolled populations. We offer proven access to priority cohorts such as the elderly, vaccine-naïve, and immunocompromised patients, critical for meeting enrollment targets and advancing equitable research.

DelRicht Research’s Track Record of Excellence in Enrollment and Approvals

DelRicht’s performance metrics speak for themselves. In the last four years alone, 10 of our sites have ranked as top enrollers in vaccine studies, and we’ve achieved first patient screened or enrolled status in at least four multicenter trials. Our contributions have supported 2 Vaccine/Flu FDA approvals, including XOFLUZA® and mRESVIA®.

Our experience spans a wide range of infectious disease indications, including Avian Influenza, COVID-19, Herpes Zoster, Influenza, Norovirus, Pneumococcal Disease, and RSV. Whether in early-phase immunogenicity studies or large-scale pivotal trials, DelRicht consistently delivers high-quality data and rapid enrollment timelines.

Ready to Accelerate Your Next Vaccine Trial

From start-up to closeout, DelRicht Research is built to perform. Sponsors and CROs partnering with us gain access to an experienced team, purpose-built infrastructure, and a network that enrolls faster and smarter, without compromising on quality. If you’re seeking a trusted partner to support your next vaccine trial, we’re ready to help you move medicine forward.